MLH1 V384D Mutation Detection for EGFR-TKI Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the efficacy of EGFR-TKI treatment in lung cancer patients are inadequate, particularly in identifying patients with primary resistance and predicting progression-free survival, due to limited understanding of genetic mechanisms underlying treatment resistance.
Innovation Solution
A method involving analysis of MLH1 protein or mRNA sequences to identify alterations at V384, such as the V384D mutation, which correlates with poor efficacy and short progression-free survival, using techniques like polymerase chain reaction, Southern blot, or Western blot.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR-TKI treatment is administered to all patients with EGFR mutations, then more patients may benefit from targeted therapy, but treatment costs increase and ineffective therapy is administered to patients with primary resistance
Solution Approach 1:
The patent applies preliminary action by performing MLH1 V384 alteration analysis before EGFR-TKI treatment to identify patients with primary resistance. This pre-treatment screening prevents ineffective therapy administration and cost waste on patients who will not respond to EGFR-TKI treatment, while ensuring that responsive patients receive the beneficial therapy.
2Loss of information
If follow-up monitoring is performed to evaluate treatment response, then treatment efficacy can be assessed, but time is lost and treatment strategies cannot be optimized promptly
Solution Approach 1:
The patent performs the evaluation action preliminarily by analyzing MLH1 V384 status before treatment initiation. This provides immediate information about expected treatment response and progression-free survival, eliminating the need for prolonged follow-up monitoring to assess whether the patient will respond to therapy.
3Reliability
If comprehensive genetic analysis is performed to understand resistance mechanisms, then treatment strategies can be optimized, but device complexity and analysis difficulty increase
Solution Approach 1:
The patent extracts the specific critical factor (MLH1 V384 alteration) from the complex landscape of genetic variations associated with EGFR-TKI resistance. Instead of analyzing all possible genetic markers, the invention focuses on this single key alteration that predicts primary resistance, thereby simplifying the diagnostic process while maintaining high predictive accuracy.
Solution Approach 2:
The patent applies local quality by concentrating analytical resources on a specific critical location (MLH1 V384) rather than performing comprehensive genome-wide analysis. This targeted approach examines only the locally critical alteration that has been identified as the key predictor of treatment response.
Data Source
AI summary
The present invention provides a method for evaluating the efficacy of an EGFR-TKI treatment to a subject, comprising identifying the V384D mutation in said subject. By identifying said mutation, the efficacy of the EGFR-TKI treatment and the progression-free survival of said subject after treatment can be estimated.